The Pharmacokinetic Profile of Voriconazole During Continuous High-volume Venovenous Hemofiltration in a Critically Ill Patient

In critically ill patients, dosage adjustment of voriconazole could be helpful when high-volume continuous venovenous hemofiltration is needed. Voriconazole pharmacokinetics were studied in an anuric critically ill patient, under high-volume continuous venovenous hemofiltration, over an interval period after a 4-mg/kg dose of voriconazole. Arterial and effluent voriconazole concentrations were measured after liquid phase extraction using a high-pressure liquid chromatography. The extrapolate area under the curve0-12h of voriconazole was 65 mg/h/L. The total body clearance of voriconazole was 5.4 L/h with a half-life of 16.5 hours and a distribution volume of 128.6 L. The estimated sieving coefficient was 0.58 and the filtration clearance 1.39 L/h. High-volume continuous venovenous hemofiltration could affect voriconazole disposition in contrast with other techniques. Besides, we observed voriconazole accumulation consequence of the saturation of the metabolic clearance resulting from multiple organ failure. Dosage adjustment seems to be required in these conditions, but this observation must be confirmed by a clinical study.

[1]  M. Shimizu,et al.  Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. , 2007, Biochemical pharmacology.

[2]  L. Gordon,et al.  Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients , 2007, Cancer.

[3]  D. Schaer,et al.  Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. , 2006, Swiss medical weekly.

[4]  J. Burhenne,et al.  Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy , 2006, BMC clinical pharmacology.

[5]  G. Mikus,et al.  Safety of Voriconazole in a Patient with CYP2C9*2/CYP2C9*2 Genotype , 2006, Antimicrobial Agents and Chemotherapy.

[6]  D. Andes,et al.  Voriconazole Therapeutic Drug Monitoring , 2006, Antimicrobial Agents and Chemotherapy.

[7]  W. Salzer,et al.  Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  T. Buclin,et al.  Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient. , 2004, The Journal of antimicrobial chemotherapy.

[9]  N. Wood,et al.  Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. , 2003, British journal of clinical pharmacology.

[10]  C. A. Kauffman,et al.  Voriconazole: a new triazole antifungal agent. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[12]  N. Wood,et al.  Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens , 2002, Antimicrobial Agents and Chemotherapy.

[13]  E. Thiel,et al.  Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  D. Stopher,et al.  A rapid HPLC assay for voriconazole in human plasma. , 1998, Journal of pharmaceutical and biomedical analysis.

[15]  H. Derendorf,et al.  Pharmacokinetic/Pharmacodynamic Profile of Posaconazole , 2010, Clinical pharmacokinetics.

[16]  H. Derendorf,et al.  Pharmacokinetic/Pharmacodynamic Profile of Voriconazole , 2006, Clinical pharmacokinetics.

[17]  A. Grootendorst,et al.  High volume hemofiltration improves right ventricular function in endotoxin-induced shock in the pig , 2005, Intensive Care Medicine.

[18]  A. Sitges-Serra,et al.  Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy , 1997, Intensive Care Medicine.